Michelle Teodoro Alves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michelle Teodoro Alves has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Luci Maria SantAna Dusse
Federal University of Minas Gerais, Faculty of Pharmacy, Belo Horizonte, Brazil
8 shared publications - Karina Braga Gomes
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
6 shared publications Ana Paula Fernandes
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
4 shared publicationsMaria das Graças Carvalho
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
4 shared publicationsAna P. Fernandes
2 shared publicationsGuilherme Victor Oliveira Pimenta dos Reis
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
2 shared publications
Latest Publications
- Open Access
- 30 August 2018
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 35 (1) , e3071
The dual effect of C‐peptide on cellular activation and atherosclerosis: Protective or not?
Summary: C‐peptide is a cleavage product of proinsulin that acts on different type of cells, such as blood and endothelial cells. C‐peptide biological effects may be different in type 1 and type 2 diabetes. Besides, there are further evidence for a functional interaction between C‐peptide and insulin. In this way, C‐peptide has ambiguous effects, acting as an antithrombotic or thrombotic molecule, depending on the physiological environment and disease conditions. Moreover, C‐peptide regulates interaction of leucocytes, erythrocytes, and platelets with the endothelium. The beneficial effects include stimulation of nitric oxide production with its subsequent release by platelets and endothelium, the interaction with erythrocytes leading to the generation of adenosine triphosphate, and inhibition of atherogenic cytokine release. The undesirable action of C‐peptide includes the chemotaxis of monocytes, lymphocytes, and smooth muscle cells. Also, C‐peptide was related with increased lipid deposits and elevated smooth muscle cells proliferation in the vessel wall, contributing to atherosclerosis. Purpose of this review is to explore these dual roles of C‐peptide on the blood, contributing at one side to haemostasis and the other to atherosclerotic process.
- 30 August 2018
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 35 (1) , e3071
Open AccessThe dual effect of C‐peptide on cellular activation and atherosclerosis: Protective or not?
Summary: C‐peptide is a cleavage product of proinsulin that acts on different type of cells, such as blood and endothelial cells. C‐peptide biological effects may be different in type 1 and type 2 diabetes. Besides, there are further evidence for a functional interaction between C‐peptide and insulin. In this way, C‐peptide has ambiguous effects, acting as an antithrombotic or thrombotic molecule, depending on the physiological environment and disease conditions. Moreover, C‐peptide regulates interaction of leucocytes, erythrocytes, and platelets with the endothelium. The beneficial effects include stimulation of nitric oxide production with its subsequent release by platelets and endothelium, the interaction with erythrocytes leading to the generation of adenosine triphosphate, and inhibition of atherogenic cytokine release. The undesirable action of C‐peptide includes the chemotaxis of monocytes, lymphocytes, and smooth muscle cells. Also, C‐peptide was related with increased lipid deposits and elevated smooth muscle cells proliferation in the vessel wall, contributing to atherosclerosis. Purpose of this review is to explore these dual roles of C‐peptide on the blood, contributing at one side to haemostasis and the other to atherosclerotic process.
- 1 October 2017
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 35, 20-26
Duffy blood group system: New genotyping method and distribution in a Brazilian extra-Amazonian population
- 1 October 2017
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 35, 20-26
Duffy blood group system: New genotyping method and distribution in a Brazilian extra-Amazonian population
- 25 July 2017
- Published by Elsevier in Thrombosis Research
- Vol. 157, 167-169
Liver up-regulation of ADAMTS13 gene expression and its correlation with renal markers in mice with type 1 diabetes mellitus and nephropathy
- 25 July 2017
- Published by Elsevier in Thrombosis Research
- Vol. 157, 167-169
Liver up-regulation of ADAMTS13 gene expression and its correlation with renal markers in mice with type 1 diabetes mellitus and nephropathy
- 27 January 2017
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 43 (3) , 436-446
Vitamin D receptor polymorphisms and the polycystic ovary syndrome: A systematic review
Polycystic ovary syndrome (PCOS) is the most frequent endocrinological disorder that affects women of reproductive age, leading to metabolic alterations, such as hyperandrogenism, obesity, menstrual irregularities, insulin resistance, and polycystic ovaries. The etiology remains unclear, but several genetic and environmental factors have been correlated with manifestations of this syndrome. Vitamin D plays important roles in metabolic pathways affected by PCOS, including calcium homeostasis, the insulin pathway, and sex hormone synthesis. Vitamin D concentration has been related with the severity of this disorder, and vitamin D receptor polymorphisms have been shown in some studies to have an association with some of the patterns presented by PCOS. The objective of this study is to provide an up‐to‐date review about vitamin D receptor polymorphisms and their association with PCOS.
- 27 January 2017
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 43 (3) , 436-446
Vitamin D receptor polymorphisms and the polycystic ovary syndrome: A systematic review
Polycystic ovary syndrome (PCOS) is the most frequent endocrinological disorder that affects women of reproductive age, leading to metabolic alterations, such as hyperandrogenism, obesity, menstrual irregularities, insulin resistance, and polycystic ovaries. The etiology remains unclear, but several genetic and environmental factors have been correlated with manifestations of this syndrome. Vitamin D plays important roles in metabolic pathways affected by PCOS, including calcium homeostasis, the insulin pathway, and sex hormone synthesis. Vitamin D concentration has been related with the severity of this disorder, and vitamin D receptor polymorphisms have been shown in some studies to have an association with some of the patterns presented by PCOS. The objective of this study is to provide an up‐to‐date review about vitamin D receptor polymorphisms and their association with PCOS.
- Open Access
- 1 May 2015
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 37 (3) , 190-197
Resistance of dialyzed patients to erythropoietin
- 1 May 2015
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 37 (3) , 190-197
Open AccessResistance of dialyzed patients to erythropoietin
- 1 March 2015
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 26 (2) , 123-130
Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus
Type 2 diabetes mellitus (DM2) is a metabolic disorder associated with hyperactivation of platelets, increased formation of platelet microparticles (PMPs) and oxidative stress that are related to cardiovascular complications. Acetylsalicylic acid (ASA) is an antiplatelet agent used in the prevention of atherothrombosis. The aim of this study was to evaluate the effect of ASA by means of platelet activation and oxidative profile. We collected blood samples of 81 patients with DM2 before and during ASA treatment. These samples were analyzed to determine the levels of 2,3-dinor thromboxane-B2 (2,3-dinor-TXB2), PMPs, thiobarbituric acid reactive species (TBARS) and 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT). Moreover, the relationship between the levels of 2,3-dinor-TXB2 with some clinical and laboratory variables such as glycated hemoglobin, platelet count, D dimer, low-density lipoprotein cholesterol and glycoprotein IIb/IIIa and cyclooxygenase-1 polymorphisms was evaluated. ASA intake did not change the levels of PMP, TBARS and MTT. Although a significant decrease in the levels of 2,3 dinorTXB2 (P < 0.001) in patients under ASA has been observed, an equal and satisfactory response to this drug was not found. However, the presence of PIA2 allele in GPIIIa gene may be associated with a better response to ASA intake in these patients, whereas other clinical and laboratory variables showed no association with this drug use. These findings are consistent with previous reports in the literature that patients with DM2 do not benefit in an equal way from the use of ASA for primary prevention of atherothrombotic events.
- 1 March 2015
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 26 (2) , 123-130
Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus
Type 2 diabetes mellitus (DM2) is a metabolic disorder associated with hyperactivation of platelets, increased formation of platelet microparticles (PMPs) and oxidative stress that are related to cardiovascular complications. Acetylsalicylic acid (ASA) is an antiplatelet agent used in the prevention of atherothrombosis. The aim of this study was to evaluate the effect of ASA by means of platelet activation and oxidative profile. We collected blood samples of 81 patients with DM2 before and during ASA treatment. These samples were analyzed to determine the levels of 2,3-dinor thromboxane-B2 (2,3-dinor-TXB2), PMPs, thiobarbituric acid reactive species (TBARS) and 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT). Moreover, the relationship between the levels of 2,3-dinor-TXB2 with some clinical and laboratory variables such as glycated hemoglobin, platelet count, D dimer, low-density lipoprotein cholesterol and glycoprotein IIb/IIIa and cyclooxygenase-1 polymorphisms was evaluated. ASA intake did not change the levels of PMP, TBARS and MTT. Although a significant decrease in the levels of 2,3 dinorTXB2 (P < 0.001) in patients under ASA has been observed, an equal and satisfactory response to this drug was not found. However, the presence of PIA2 allele in GPIIIa gene may be associated with a better response to ASA intake in these patients, whereas other clinical and laboratory variables showed no association with this drug use. These findings are consistent with previous reports in the literature that patients with DM2 do not benefit in an equal way from the use of ASA for primary prevention of atherothrombotic events.
- Open Access
- 23 January 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 28
Human parvovirus B19 infection in a renal transplant recipient: a case report
Background: Parvovirus B19 presents tropism for human erythroid progenitor cells, causing chronic anemia in organ transplant recipients, due to their suppressed humoral and cellular responses. Diagnosis may be achieved through serological tests for detection of anti-B19 antibodies. However, renal transplant recipients are not routinely tested for parvovirus B19 infection, since there is scanty data or consensus on screening for B19 infection, as well as for treatment or preventive management of transplanted patients. Case presentation: Herein we report a kidney transplant recipient, who was unresponsive to treatment of severe anemia, and presented hypocellular hematopoietic marrow, megaloblastosis and hypoplasia of erythroid lineage with larger cells with clear nuclei chromatin and eosinophilic nuclear inclusions. This patient was seropositive for Epstein-Barr and Cytomegalovirus infections and negative for anti-parvovirus B19 IgM and IgG antibodies, although symptoms were suggestive of parvoviruses infection. A qualitative polymerase chain reaction testing for B19 in serum sample revealed positive results for B19 virus DNA. Conclusion: This case report suggests that the diagnostic process for parvovirus B19 in renal transplant recipients should include a polymerase chain reaction assay to detect B19-DNA, since specific serological tests may be unreliable given their impaired humoral responses. These results also indicate the importance of considering parvovirus B19 infection in the differential diagnosis of persistent anemia in transplanted patients.
- 23 January 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 28
Open AccessHuman parvovirus B19 infection in a renal transplant recipient: a case report
Background: Parvovirus B19 presents tropism for human erythroid progenitor cells, causing chronic anemia in organ transplant recipients, due to their suppressed humoral and cellular responses. Diagnosis may be achieved through serological tests for detection of anti-B19 antibodies. However, renal transplant recipients are not routinely tested for parvovirus B19 infection, since there is scanty data or consensus on screening for B19 infection, as well as for treatment or preventive management of transplanted patients. Case presentation: Herein we report a kidney transplant recipient, who was unresponsive to treatment of severe anemia, and presented hypocellular hematopoietic marrow, megaloblastosis and hypoplasia of erythroid lineage with larger cells with clear nuclei chromatin and eosinophilic nuclear inclusions. This patient was seropositive for Epstein-Barr and Cytomegalovirus infections and negative for anti-parvovirus B19 IgM and IgG antibodies, although symptoms were suggestive of parvoviruses infection. A qualitative polymerase chain reaction testing for B19 in serum sample revealed positive results for B19 virus DNA. Conclusion: This case report suggests that the diagnostic process for parvovirus B19 in renal transplant recipients should include a polymerase chain reaction assay to detect B19-DNA, since specific serological tests may be unreliable given their impaired humoral responses. These results also indicate the importance of considering parvovirus B19 infection in the differential diagnosis of persistent anemia in transplanted patients.
- 1 July 2011
- Published by Elsevier in Clinica Chimica Acta
- Vol. 412 (15-16) , 1366-1370
Urinary 11-dehydro thromboxane B2 levels in type 2 diabetic patients before and during aspirin intake
- 1 July 2011
- Published by Elsevier in Clinica Chimica Acta
- Vol. 412 (15-16) , 1366-1370
Urinary 11-dehydro thromboxane B2 levels in type 2 diabetic patients before and during aspirin intake
- 28 May 2011
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 357 (1-2) , 247-253
HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women
Genetic factors related to cancer have been extensively studied and several polymorphisms have been associated to breast cancer. The FGFR4, MTHFR, and HFE genes have been associated with neoplastic diseases development. The current report outlines the analysis of the polymorphisms G388A (FGFR4), C677T (MTHFR), C282Y, and H63D (HFE) in Brazilian breast cancer patients. We studied 68 patients with invasive ductal and operable breast carcinoma and 85 women as a control group. The polymorphism frequencies in the breast cancer and control groups were analyzed, but no significant difference was observed by comparing the two groups. The presence of each polymorphism was analyzed according to the clinical features and markers already established as prognostic in the breast cancer group. The C677T, H63D, and G388A polymorphisms were not associated to histological grade, age of diagnosis, expression of HER2 receptor, or estrogen and progesterone receptor. The H63D polymorphism showed a significant association (P = 0.02) with the presence of p53 mutations, and C667T showed association to lymph node involvement (P = 0.05). Lymph node involvement, G388A polymorphism, and histological grade were independently associated to metastasis/death. Our data suggests that the polymorphisms G388A, C677T, and H63D are not useful in breast cancer diagnosis, but they may be significant additional prognostic markers related to breast cancer survival.
- 28 May 2011
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 357 (1-2) , 247-253
HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women
Genetic factors related to cancer have been extensively studied and several polymorphisms have been associated to breast cancer. The FGFR4, MTHFR, and HFE genes have been associated with neoplastic diseases development. The current report outlines the analysis of the polymorphisms G388A (FGFR4), C677T (MTHFR), C282Y, and H63D (HFE) in Brazilian breast cancer patients. We studied 68 patients with invasive ductal and operable breast carcinoma and 85 women as a control group. The polymorphism frequencies in the breast cancer and control groups were analyzed, but no significant difference was observed by comparing the two groups. The presence of each polymorphism was analyzed according to the clinical features and markers already established as prognostic in the breast cancer group. The C677T, H63D, and G388A polymorphisms were not associated to histological grade, age of diagnosis, expression of HER2 receptor, or estrogen and progesterone receptor. The H63D polymorphism showed a significant association (P = 0.02) with the presence of p53 mutations, and C667T showed association to lymph node involvement (P = 0.05). Lymph node involvement, G388A polymorphism, and histological grade were independently associated to metastasis/death. Our data suggests that the polymorphisms G388A, C677T, and H63D are not useful in breast cancer diagnosis, but they may be significant additional prognostic markers related to breast cancer survival.